Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea

Molecular Nutrition and Food Research

Volumn 52, Issue 7, 2008, Pages 755-763

  Gurley, Bill J ^a   Swain, Ashley ^b   Hubbard, Martha A ^a   Williams, D Keith ^b   Barone, Gary ^b   Hartsfield, Faith ^a   Tong, Yudong ^a   Carrier, Danielle J ^c   Cheboyina, Shreekar ^d   Battu, Sunil K ^d  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c 3202 Bell Engineering Center   (United States)

^d UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Botanical supplements; Cytochrome P450 2D6; Debrisoquine; Goldenseal; Herb drug interactions

Indexed keywords

CIMICIFUGA DAHURICA; CIMICIFUGA RACEMOSA; ECHINACEA PURPUREA; HYDRASTIS; HYDRASTIS CANADENSIS; HYPERICUM PERFORATUM; PIPER METHYSTICUM; SILYBUM MARIANUM;

CYTOCHROME P450 2D6; KAVA; PLANT EXTRACT;

ARTICLE; CIMICIFUGA; DIET SUPPLEMENTATION; ECHINACEA; HERB DRUG INTERACTION; HUMAN; HYDRASTIS; HYPERICUM; METABOLISM; PHYTOTHERAPY; SILYBUM MARIANUM;

CIMICIFUGA; CYTOCHROME P-450 CYP2D6; DIETARY SUPPLEMENTS; ECHINACEA; HERB-DRUG INTERACTIONS; HUMANS; HYDRASTIS; HYPERICUM; KAVA; MILK THISTLE; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 53249123498     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.200600300     Document Type: Article

References (80)

1. Brazier, N. C., Levine, M. A. H., Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am. J. Ther. 2003, 10, 163-169.
2. Hu, Z., Yang, X., Ho, P. C. L., Chan, S. Y., et al., Herb-drug interactions: a literature review. Drugs 2005, 65, 1239-1282.
3. Johne, A., Roots, I., Clinical drug interactions with medicinal herbs. Evid. Based Integrative Med. 2005, 2, 207-228.
4. Wold, R. S., Lopez, S. T., Yau, L., Butler, L. M., et al., Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medications. J. Am. Diet. Assoc. 2005, 105, 54-63.
5. Shahrokh, L. E., Lukaszuk, J. M., Prawitz, A. D., Elderly herbal supplement users less satisfied with medical care than nonusers. J. Am. Diet. Assoc. 2005, 105, 1138-1140.
6. Gardiner, P., Graham, R. E., Legedza, A. T. R., Eisenberg, D. M., Phillips, R. S., Factors associated with dietary supplement use among prescription medication users. Arch. Intern. Med. 2006, 166, 1968-1974.
7. Delgoda, R., Westlake, A. C. G., Herbal interactions involving cytochrome P450 enzymes. Toxicol. Rev. 2004, 23, 239-249.
8. Zhou, S., Chan, E., Pan, S.-Q., Huang, M., Lee, E. J. D., Pharmacokinetic interactions of drugs with St John's wort. J. Psychopharmacol. 2004, 18, 262-276.
9. Tirona, R. G., Bailey, D. G., Herbal product - drug interactions mediated by induction. Br. J. Clin. Pharmacol. 2006, 61, 677-681.
10. Whitten, D. L., Myers, S. P., Hawrelak, J. A., Wohlmuth, H., The effect of St John's wort extracts on CYP3A4: a systematic review of prospective clinical trials. Br. J. Clin. Pharmacol. 2006, 62, 512-526.
11. Barone, G. W., Gurley, B. J., Ketel, B. L., Lightfoot, M. L., Abul-Ezz, S. R., Drug interaction between St. John's wort and cyclosporine. Ann. Pharmacother. 2000, 34, 1013-1016.
12. Barone, G. W., Gurley, B. J., Ketel, B. L., Abul-Ezz, S. R., Herbal dietary supplements: a source for drug interactions in transplant recipients. Transplantation 2001, 71, 239-241.
13. Wentworth, J. M., Agostini, M., Love, J., Schwabe, J. W., Chatterjee, V. K. K., St. John's wort, a herbal antidepressant, activates the steroid X receptor. J. Endocrinol, 2000, 166, R11-R16.
14. Ingelman-Sundberg, M., Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 2005, 5, 6-13.
15. Sugimoto, K., Ohmori, M., Tsuruoka, S., Nishiki, K., et al., Different effects of St. John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 2001, 70, 518-524.
16. Piscitelli, S. C., Burstein, A. H., Welden, N., Gallicano, K. D., Falloon, J., The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin. Infect. Dis. 2002, 34, 234-238.
17. Gallicano, K., Foster, B., Choudhri, S., Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br. J. Clin. Pharmacol. 2003, 55, 199-202.
18. Sandhu, R. S., Prescilla, R. P., Simonelli, T. M., Edwards, D. J., Influence of goldenseal root on the pharmacokinetics of indinavir. J. Clin. Pharmacol. 2003, 43, 1283-1288.
19. Hall, S. D., Wang, Z., Huang, S.-M., Hamman, M. A., et al., The interaction between St. John's wort and an oral contraceptive. Clin. Pharmacol. Ther. 2003, 74, 525-535.
20. Anderson, G. D., Rosito, G., Mohustsy, M. A., Elmer, G. W., Drug interaction potential of soy extract and panax ginseng. J. Clin. Pharmacol. 2003, 43, 643-648.
21. DiCenzo, R., Shelton, M., Jordan, K., Koval, C., et al., Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003, 23, 866-870.
22. Rajnarayana, K., Reddy, M. S., Vidyasagar, J., Krishna, D. R., Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneim. Forsch./Drug Res. 2004, 54, 109-113.
23. van Erp, N. P. H., Baker, S. D., Zhao, M., Rudek, M. A., et al., Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin. Cancer Res. 2005, 11, 7800-7806.
24. Mills, E., Wilson, K., Clarke, M., Foster, B., et al., Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta analysis. Eur. J. Clin. Pharmacol. 2005, 61, 1-7.
25. Gurley, B., Hubbard, M. A., Williams, D. K., Thaden, J., et al., Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J. Clin. Pharmacol. 2006, 46, 201-213.
26. Cox, M. C., Low, J., Lee, J., Walshe, J., et al., Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin. Cancer Res. 2006, 12, 4636-4640.
27. Uchida, S., Yamada, H., Li, X. D., Maruyama, S., et al., Effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J. Clin. Pharmacol. 2006, 46, 1290-1298.
28. Portolés, A., Terleira, A., Calvo, A., Martínez, I., et al., Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J. Clin. Pharmacol. 2006, 46, 1188-1194.
29. Markowitz, J. S., DeVane, C. L., Boulton, D. W., Carson, S. W., Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Pharmacol. Lett. 2000, 66, 133-139.
30. Roby, C. A., Dryer, D. A., Burstein, A. H., St. John's wort: effect on CYP2D6 activity using dextromethorphan-dextrorphan ratios. J. Clin. Psychopharmacol. 2001, 21, 530-532.
31. Wang, Z., Gorski, J. C., Hamman, M. A., Huang, S.-M., et al., The effects of St. John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin. Pharmacol. Ther. 2001, 70, 317-326.
32. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin. Pharmacol. Ther. 2002, 72, 276-282.
33. Markowitz, J. S., DeVane, C. L., Chavin, K. D., Taylor, R. M., et al., Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin. Pharmacol. Ther. 2003, 74, 170-177.
34. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., et al., Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003, 290, 1500-1504.
35. Markowitz, J. S., Donovan, J. L., DeVane, C. L., Taylor, R. M., et al., Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin. Pharmacol. Ther. 2003, 74, 536-542.
36. Markowitz, J. S., Donovan, J. L., Devane, C. L., Sipkes, L., Chavin, K. D., Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J. Clin. Psychopharmacol 2003, 23, 576-581.
37. Gorski, J. C., Huang, S.-M., Pinto, A., Hamman, M. A., The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin. Pharmacol. Ther. 2004, 75, 89-100.
38. Wenk, M., Todesco, L., Krähenbühl, S., Effect of St. John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, Nacetyltransferase 2, and xanthine oxidase in healthy males and females. Br. J. Clin. Pharmacol. 2004, 57, 495-499.
39. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin. Pharmacol. Ther. 2004, 76, 428-440.
40. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St. John's wort, garlic oil, panax ginseng, and ginkgo biloba. Drugs Aging 2005, 22, 525-539.
41. Branch, R. A., Adedoyin, A., Frye, R. F., Wilson, J. W., Romkes, M., In vivo modulation of CYP enzymes by quinidine and rifampin. Clin. Pharmacol. Ther. 2000, 68, 401-411.
42. Edwards, R. J., Price, R. J., Watts, P. S., Renwick, A. B., et al., Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab. Dispos. 2003, 31, 282-288.
43. Madan, A., Graham, R. A., Carroll, K. M., Mudra, D. R., et al., Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab. Dispos. 2003, 31, 421-431.
44. Streetman, D. S., Bertino, J. S., Nafziger, A. N., Phenotyping of drug metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10, 187-216.
45. Frye, R. F., Matzke, G. R., Adedoyin, A., Porter, J. A., Branch, R. A., Validation of the five-drug "Pittsburg cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin. Pharmacol. Ther. 1997, 62, 365-376.
46. Özdemir, M., Crewe, K. H., Tucker, G. T., Rostami-Hodjean, A., Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J. Clin. Pharmacol. 2004, 44, 1398-1404.
47. Frank, D., Jaehde, U., Fuhr, U., Evaluation of probe drugs and pharmacokinetic metric for CYP2D6 phenotyping. Eur. J. Clin. Pharmacol. 2007, 63, 321-333.
48. Russman, S., Helbing, A., Kava hepatoxicity. Ann. Int. Med. 2001, 135, 68-69.
49. Clough, A. R., Bailie, R. S., Currie, B., Liver function test abnormalities in users of aqueous kava extracts. J. Toxicol. Clin. Toxicol. 2003, 41, 821-829.
50. Frye, R. F., Branch, R. A., Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquin in human urine following direct injection. J. Chromatogr. B Biomed. Appl. 1996, 677, 178-182.
51. Abourashed, E. A., Khan, I. A., High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J. Pharm. Sci. 2001, 90, 817-822.
52. Ganzera, M., Khan, I. A., Analytical techniques for the determination of lactones in Piper methysticum Forst. Chromatographia 1999, 50, 649-653.
53. Ganzera, M., Bedir, E., Khan, I. A., Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection. Chromatographia 2000, 52, 301-304.
54. Gurley, B. J., Barone, G. W., Williams, D. K., Carrier, J. C., et al., Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab. Dispos. 2006, 34, 69-74.
55. Liu, F. F., Ang, C. Y. W., Heinze, T. M., Rankin, J. D., et al., Evaluation of major active components in St. John's wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation. J. Chromatogr. A 2000, 888, 85-92.
56. Molgaard, P., Johnsen, S., Christensen, P., Cornett, C., HPLC method validated for the simultaneous analysis of cichoric acid and alkamides in Echinacea purpurea planta and products. J. Agric. Food Chem. 2003, 51, 6922-6933.
57. nd ed., United States Pharmacopeial Convention, Inc., Rockville 2004, pp. 2645-2646.
58. nd ed., Lawrence Erlbaum Associates, Hillsdale, NJ, 1988.
59. Foster, B. C., Vandenhoek, S., Hana, J., Krantis, A., et al., In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003, 10, 334-342.
60. Chatterjee, P., Franklin, M. R., Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 2003, 31, 1391-1397.
61. Beckmann-Knopp, S., Rietbrock, S., Weyhenmeyer, R., Böcker, R. H., et al., Inhibitory effects of silibinin on cytochromes P-450 enzymes in human liver microsomes. Pharmacol. Toxicol. 2000, 86, 250-256.
62. Zuber, R., Modriansky, M., Dvorák, Z., Rohovsky, P., et al., Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother. Res. 2002, 16, 632-638.
63. Matthews, J. M., Etheridge, A. S., Black, S. R., et al., Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 2002, 30, 1153-1157.
64. Unger, M., Frank, A., Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun. Mass Spectrom. 2004, 18, 2273-2281.
65. Clayton, N. P., Yoshizawa, K., Kissling, G. E., Burka, L. T., et al., Immunohistochemical analysis of expression of hepatic cytochrome P450 in F344 rats following treatment with kava extract. Exp. Toxicol. Path. 2007, 58, 223-236.
66. Obach, R. S., Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J. Pharmacol. Exp. Ther. 2000, 294, 88-95.
67. Zou, L., Harkey, M. R., Henderson, G. L., Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002, 71, 1579-1589.
68. Hodek, P., Trefil, P., Stiborová, M., Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chemico-Biol. Int. 2002, 139, 1-21.
69. Tsukamoto, S., Aburatani, M., Ohta, T., Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM 2005, 2, 223-226.
70. von Moltke, L. L., Greenblatt, D. J., Schmider, J., Wright, C. E., et al., In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 1998, 55, 113-122.
71. Wallace, S., Carrier, D. J., Clausen, E. C., Extraction of nutraceuticals from milk thistle. Appl. Biochem. Biotech. 2003, 105-108, 891-903.
72. Gilroy, C. M., Steiner, J. F., Byers, T., Shapiro, H., Georgian, W., Echinacea and truth in labeling. Arch. Intern. Med. 2003, 163, 699-704.
73. Jiang, B., Kronenberg, F., Nuntanakorn, P., Qiu, M.-H., Kennelly, E. J., Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry. J. Agric. Food Chem. 2006, 54, 3242-3253.
74. De Los Reyes, G. C., Koda, R. T., Determining hyperforin and hypericin content in eight brands of St. John's wort. Am. J. Health-Syst. Pharm. 2002, 59, 545-547.
75. Manach, C., Scalbert, A., Morand, C., Rémésy, C., Jiménez, L., Polyphenols: food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727-747.
76. Gurley, B. J., Gardner, S. F., Hubbard, M. A., Williams, D. K., et al., In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 2005, 77, 415-426.
77. Labbé, L., Sirois, C., Pilote, S., Arseneault, M., et al., Effect of gender, sex hormones, time tables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics 2000, 10, 425-438.
78. Borges, S., Li, L., Hamman, M. A., Jones, D. R., Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance. Drug Metab Dispos. 2005, 33, 1052-1055.
79. Bhide, M. B., Chavan, S. R., Dutta, N. K., Absorption, distribution and excretion of berberine. Ind. J. Med. Res. 1969, 57, 2128-2131.
80. Pan, G., Wang, G.-J., Liu, X.-D., Fawcett, J. P., Xie, Y.-Y., The involvement of p-glycoprotein in berberine absorption. Pharmacol. Toxicol. 2002, 91, 193-197.